Trimethoprim Use prior to Pregnancy and the Risk of Congenital Malformation: A Register-Based Nationwide Cohort Study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Trimethoprim Use prior to Pregnancy and the Risk of Congenital Malformation : A Register-Based Nationwide Cohort Study. / Andersen, Jon Traerup; Petersen, Morten; Jimenez-Solem, Espen; Rasmussen, Jeppe Norgaard; Andersen, Nadia Lyhne; Afzal, Shoaib; Broedbaek, Kasper; Hjelvang, Brian Rafn; Kober, Lars; Torp-Pedersen, Christian; Poulsen, Henrik Enghusen.
I: Obstetrics and Gynecology International, Bind 2013, 364526, 2013.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Trimethoprim Use prior to Pregnancy and the Risk of Congenital Malformation
T2 - A Register-Based Nationwide Cohort Study
AU - Andersen, Jon Traerup
AU - Petersen, Morten
AU - Jimenez-Solem, Espen
AU - Rasmussen, Jeppe Norgaard
AU - Andersen, Nadia Lyhne
AU - Afzal, Shoaib
AU - Broedbaek, Kasper
AU - Hjelvang, Brian Rafn
AU - Kober, Lars
AU - Torp-Pedersen, Christian
AU - Poulsen, Henrik Enghusen
PY - 2013
Y1 - 2013
N2 - Objectives. The aim of the study was to investigate whether the use of the antifolate antibiotic trimethoprim during the 12 weeks before conception was associated with congenital malformations. Methods. We conducted a nationwide register-based cohort study including all Danish women giving birth from 1997 to 2004. All women with at least one prescription of trimethoprim dispensed during the 12 weeks before conception were identified. Results. There was a doubling of congenital malformations in offspring to women exposed to trimethoprim in the 12weeks before conception. The adjusted odds ratio (OR) of major congenitalmalformation was 1.87, 95% confidence interval (CI) 1.25-2.81. There was a significant increase in major malformations of the heart (OR = 2.49; 1.18-5.26) and limbs (OR = 2.18; 1.13-4.23). Conclusions. In this study, we found an association between exposure to trimethoprim during the 12 weeks before conception and an increased risk of heart and limb defects.
AB - Objectives. The aim of the study was to investigate whether the use of the antifolate antibiotic trimethoprim during the 12 weeks before conception was associated with congenital malformations. Methods. We conducted a nationwide register-based cohort study including all Danish women giving birth from 1997 to 2004. All women with at least one prescription of trimethoprim dispensed during the 12 weeks before conception were identified. Results. There was a doubling of congenital malformations in offspring to women exposed to trimethoprim in the 12weeks before conception. The adjusted odds ratio (OR) of major congenitalmalformation was 1.87, 95% confidence interval (CI) 1.25-2.81. There was a significant increase in major malformations of the heart (OR = 2.49; 1.18-5.26) and limbs (OR = 2.18; 1.13-4.23). Conclusions. In this study, we found an association between exposure to trimethoprim during the 12 weeks before conception and an increased risk of heart and limb defects.
KW - NEURAL-TUBE DEFECTS
KW - PERICONCEPTIONAL MULTIVITAMIN USE
KW - FOLIC-ACID ANTAGONISTS
KW - DANISH
KW - SUPPLEMENTATION
KW - RECOMMENDATIONS
KW - METHOTREXATE
KW - REGISTRATION
KW - PROPHYLAXIS
KW - FERTILITY
U2 - 10.1155/2013/364526
DO - 10.1155/2013/364526
M3 - Journal article
VL - 2013
JO - Obstetrics and Gynecology International
JF - Obstetrics and Gynecology International
SN - 1687-9589
M1 - 364526
ER -
ID: 322490399